Brian Underdown

VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions.

Ellipsis Neurotherapeutics, Inc. develops pharmaceutical products for treatment and preventing of Alzheimer's disease and related disorders. The firm commercializes neurodegenerative disease therapeutics and diagnostics. The company was founded by Laurence Rubin in November 2004 and is headquartered in Toronto, Canada.

PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada.

MedInnova Partners, Inc is a venture capital firm, founded in 2000. The firm headquartered in Halifax, Nova Scotia.

MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario.

Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA.

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.

Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO)

NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada.

DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada.

Mcmaster Innovation Park operates as a premier research park that offers collaborative space for researchers and entrepreneurs to co-locate, connect and commercialize. The company is headquartered in Hamilton, Canada.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada.

Naegis Pharmaceuticals, Inc. manufactures pharmaceutical products. The private company is based in Vancouver, Canada.

OsteoqQC, Inc. develops drugs for the treatment of bone-related diseases. The company was founded by Debra Ellies and is headquartered in Montreal, Canada.

Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada.